TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

WuXi XDC and IntoCell Establish Collaboration to Hasten ADC Discovery and Development for Clients

Wednesday, January 03, 2024

WuXi XDC and IntoCell have recently announced the signing of a Memorandum of Understanding (MOU) to establish a comprehensive partnership in the realm of drug-linker technology and Contract Research, Development, and Manufacturing Organization (CRDMO) services throughout the drug development process. WuXi XDC, a prominent global CRDMO specializing in Antibody-Drug Conjugates (ADC) and other bioconjugates, will be collaborating with IntoCell, a Korean biotechnology company focusing on innovative ADC platform technologies.

As part of the agreement, IntoCell will contribute its proprietary drug-linker technologies, which include the Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and NexatecansTM, a novel class of OHPAS-able Camptothecins. WuXi XDC will bring to the table fully integrated, end-to-end bioconjugate platforms and CRDMO services, covering the entire drug development journey from discovery to commercialization. The overarching goal of this partnership is to expedite the selection of Pre-clinical candidates, advance next-generation ADCs, and streamline the Chemistry, Manufacturing, and Controls (CMC) development process.

Dr. Jimmy Li, CEO of WuXi XDC, expressed enthusiasm about the collaboration, stating, "IntoCell's unique drug-linker technologies and our leading, open-access platform are a great combination to enable the fast delivery of pre-clinical candidates, especially in novel ADC programs. We are delighted to establish this comprehensive partnership with IntoCell and to forge the capability synergy."

Tae Kyo Park, Founder and CEO of IntoCell, highlighted the potential benefits of the collaboration, stating, "Given WuXi XDC's ample experience and superb capabilities in the CRDMO business, along with IntoCell's proprietary drug-linker technology, the collaborative efforts of the two companies will pave an easier path for potential ADC development companies to access a variety of drug-linker sets in a stable yet fast-cleavable format. We are eager to witness positive progress towards that goal."

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit